DCTH:NASDAQ
Delcath Systems Inc
US$10.55
arrow_downward
-2.68%(-0.29) 1D
US$10.55
0.00% (0.00)
bedtimeවේලාවෙන් පසු
වසා ඇත: බක් 28, 16.00.01 ග්රිමවේ-4 · USD
search
සියලු සංකේත
1D
5D
1M
6M
YTD
1Y
5Y
උපරි
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoDCTH සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
US$10.75
ඉහළ
US$10.87
පහළ
US$10.53
වෙ.පො ප්රාග්ධනය
මි363.50
දළ පරිමාව
ද314.26
හඬ පරිමාණය
ද191.94
P/E අනුපාතය
155.97
සති-52 ඉහළ
US$18.23
සති-52 පහළ
US$8.12
EPS
US$0.07
බීටා
0.44
ගෙවිය යුතු කොටස්
මි34.46
සේවකයින් ගණන
156
පුවත් සහ කථා
වෙබය හරහා මූලාශ්ර වෙතින්
富途牛牛
·
මිනිත්තු 33කට පෙර
Dow Jones Top Financial Services Headlines at 12 AM ET: Visa Revenue Climbs as Consumers Keep Spending
富途牛牛
·
මිනිත්තු 33කට පෙර
Dow Jones Top Energy Headlines at 12 AM ET: U.A.E.'s OPEC Exit Deals Major Blow to Cartel Amid Middle East Oil Squeeze | UAE ...
MarketBeat
·
මිනිත්තු 44කට පෙර
Short Interest in Intuit Inc. (NASDAQ:INTU) Expands By 36.7%
Simply Wall Street
·
පැය 1කට පෙර
A Look At Telesat (NasdaqGS:TSAT) Valuation After Its Strong Recent Share Price Momentum
පැතිකඩ
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Delcath Systems Inc ගැන
CEOGerard Michel
සේවකයින්156
ආරම්භ කළේ1988
මූලස්ථානයQueensbury, නිව්යෝර්ක්, එක්සත් ජනපදය
අංශයMedical device
වෙබ් අඩවියdelcath.com
AI අන්තර්ගතයේ වැරදි ඇතුළත් විය හැක. තව දැන ගන්න